ClinicaliQ Trial Snapshot
- A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) — Active Not Recruiting • Phase III • Oncology • NCT04195750.
- Belzutifan compared to everolimus for advanced kidney cancer, testing if belzutifan improves survival and delays disease progression.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS. Conditions: Carcinoma, Renal Cell Interventions: Belzutifan, Everolimus Lead Sponsor: Merck Sharp & Dohme LLC Planned Enrollment: 755 participants